Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888458 | 0.87 | GRM5 (0.41) | GRM5ALDH1A1MAPTEGFRHDAC1 | |
| SCHEMBL29520611 | 0.84 | DYRK1A (0.51) | GRM5ALDH1A1MAPTEGFRHDAC1 | |
| SCHEMBL2144640 | 0.84 | DYRK1A (0.51) | GRM5ALDH1A1MAPTEGFRHDAC1 | |
| SCHEMBL434799 | 0.78 | NPC1 (0.58) | GRM5ALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL31550542 | 0.78 | SIK1 (0.40) | ALDH1A1MAPTEGFRNPC1RAB9A | |
| SCHEMBL23162291 | 0.76 | SIK1 (0.40) | ALDH1A1MAPTEGFRNPC1RAB9A | |
| SCHEMBL4814996 | 0.76 | GRM5 (0.51) | GRM5ALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL1496402 | 0.76 | FGFR1 (0.54) | GRM5ALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL16132873 | 0.76 | GRM5 (0.51) | GRM5ALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL6761540 | 0.76 | GRM5 (0.51) | GRM5ALDH1A1MAPTHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| CN-118139862-A | Nitrogen-containing heterocyclic compound and medical application thereof | 中国医药研究开发中心有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | GRM5 272/4885ALDH1A1 1260/4885MAPT 316/4885 |
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | GRM5 357/4885ALDH1A1 4611/4885MAPT 2762/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | GRM5 328/4885ALDH1A1 3236/4885MAPT 2234/4885 |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | GRM5 461/4885ALDH1A1 2879/4885MAPT 4853/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | GRM5 1224/4885ALDH1A1 1178/4885MAPT 3740/4885 |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | GRM5 3280/4885ALDH1A1 1180/4885MAPT 2233/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | GRM5 4036/4885ALDH1A1 1151/4885MAPT 4063/4885 |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | GRM5 554/4885ALDH1A1 1306/4885MAPT 3110/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | GRM5 378/4885ALDH1A1 472/4885MAPT 2623/4885 |
| US-20070142381-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | GRM5 364/4885ALDH1A1 4712/4885MAPT 2847/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | GRM5 2106/4885ALDH1A1 2320/4885MAPT 2119/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | GRM5 2192/4885ALDH1A1 4417/4885MAPT 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.